1: Root C, Smith CD, Sundseth SS, Pink HM, Wilson JG, Lewis MC. Ileal bile acid
transporter inhibition, CYP7A1 induction, and antilipemic action of 264W94. J
Lipid Res. 2002 Aug;43(8):1320-30. PMID: 12177176.
2: Chen L, Yao X, Young A, McNulty J, Anderson D, Liu Y, Nystrom C, Croom D,
Ross S, Collins J, Rajpal D, Hamlet K, Smith C, Gedulin B. Inhibition of apical
sodium-dependent bile acid transporter as a novel treatment for diabetes. Am J
Physiol Endocrinol Metab. 2012 Jan 1;302(1):E68-76. doi:
10.1152/ajpendo.00323.2011. Epub 2011 Sep 20. PMID: 21934041.
3: Saveleva EE, Tyutrina ES, Nakanishi T, Tamai I, Salmina AB. Ingibitory
natriĭ-zavisimogo perenoschika zhelchnykh kislot (ASBT) kak perspektivnye
lekarstvennye sredstva [The inhibitors of the apical sodium-dependent bile acid
transporter (ASBT) as promising drugs]. Biomed Khim. 2020 May;66(3):185-195.
Russian. doi: 10.18097/PBMC20206603185. PMID: 32588824.
4: Wu Y, Aquino CJ, Cowan DJ, Anderson DL, Ambroso JL, Bishop MJ, Boros EE, Chen
L, Cunningham A, Dobbins RL, Feldman PL, Harston LT, Kaldor IW, Klein R, Liang
X, McIntyre MS, Merrill CL, Patterson KM, Prescott JS, Ray JS, Roller SG, Yao X,
Young A, Yuen J, Collins JL. Discovery of a highly potent, nonabsorbable apical
sodium-dependent bile acid transporter inhibitor (GSK2330672) for treatment of
type 2 diabetes. J Med Chem. 2013 Jun 27;56(12):5094-114. doi:
10.1021/jm400459m. Epub 2013 Jun 6. PMID: 23678871.